<DOC>
	<DOCNO>NCT00227682</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide , dexamethasone , ascorbic acid , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Sometimes chemotherapy give , stop growth cancer cell . The cancer say resistant chemotherapy . Giving arsenic trioxide together chemotherapy may reduce drug resistance allow cancer cell kill . Thalidomide may stop growth multiple myeloma block blood flow cancer . Giving arsenic trioxide together thalidomide , dexamethasone , ascorbic acid may kill cancer cell . PURPOSE : This phase II trial study well give arsenic trioxide together thalidomide , dexamethasone , ascorbic acid work treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Arsenic Trioxide , Thalidomide , Dexamethasone , Ascorbic Acid Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety side effect arsenic trioxide administer combination thalidomide , dexamethasone , ascorbic acid patient relapse refractory multiple myeloma . - Determine , preliminarily , anticancer effect regimen patient . - Determine duration anticancer effect patient treat regimen . - Determine effect regimen bone immune function patient . OUTLINE : Patients receive arsenic trioxide IV continuously oral ascorbic acid daily day 1-5 week 1 twice weekly week 2-12 oral thalidomide daily week 1-14 . Treatment arsenic trioxide , ascorbic acid , thalidomide repeat every 14 week 4 course absence disease progression unacceptable toxicity . Patients also receive oral dexamethasone daily day 1-4 . Treatment dexamethasone repeat every 28 day . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma ( MM ) Relapsed refractory disease Monoclonal immunoglobulin spike serum electrophoresis ≥ 1 gm/dL AND/OR urine monoclonal immunoglobulin spike ≥ 200 mg/24 hour Has receive ≥ 2 prior treatment regimen MM None follow allow : Nonsecretory MM Plasma cell leukemia Polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ( POEMS ) syndrome PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic Platelet count ≥ 50,000/mm^3 ( 30,000/mm^3 bone marrow extensively infiltrate ) Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 1,000/mm^3 Hepatic AST ALT &lt; 3.0 time upper limit normal ( ULN ) Bilirubin &lt; 2.0 time ULN Renal Not specify Cardiovascular No cardiac disease , include follow condition : History recurrent supraventricular arrhythmia History sustain ventricular tachycardia History second third degree AV block History leave bundle branch block Cardiomyopathy LVEF &lt; 40 % Uncontrolled ischemic heart disease No myocardial infarction within past 6 month No prolong QT interval &gt; 500 m Other Not pregnant nursing Negative pregnancy test No HIV positivity No neuropathy &gt; grade 3 Potassium ≥ 4 mEq/L Magnesium ≥ 1.8 mg/dL PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>